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Abstract
Background: The effectiveness of rotavirus vaccines in low and very low birth weight infants 
(LBW and VLBW) weighing <2500 and <1500 g at birth, respectively, a high-risk population for 
severe rotavirus gastroenteritis, has not been well examined.
Methods: We analyzed inpatient commercial claims data for US children <5 years of age from 
July 2001 to June 2015. Claims for acute gastroenteritis (AGE) and rotavirus-coded 
hospitalizations and LBW, VLBW and normal birth weight (NBW) infants were identified. 
Receipt of rotavirus vaccine was defined using Current Procedural Terminology. Rate reductions 
were calculated using prevaccine (2001–2006) and postvaccine (2007–2015) annual AGE and 
rotavirus hospitalization rates.
Results: As of December 2014, rotavirus vaccine coverage was 87%, 82% and 64%, for NBW, 
LBW and VLBW infants, respectively. For 2014–2015, among NBW, LBW and VLBW children 
<5 years of age, AGE hospitalization rate reductions relative to the prevaccine introduction period 
were 60% [95% confidence interval (CI): 58%–61%], 64% (95% CI: 57%–70%) and 55% (95% 
CI: 39%–67%), respectively. Rotavirus hospitalization rate reductions were 91% (95% CI: 90%–
92%), 98% (95% CI: 93%–100%) and 93% (95% CI: 70%–98%). Rotavirus vaccines resulted in a 
62% (95% CI: 51%–71%), 72% (95% CI: 44%–86%) and 71% (95% CI: 7%–91%) reduction in 
AGE hospitalization rates comparing vaccinated versus unvaccinated NBW, LBW and VLBW 
children 3–23 months of age, respectively.
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Conclusions: Rotavirus vaccines have substantially reduced AGE hospitalizations and are 
highly effective in LBW and VLBW infants, similar to NBW infants. Efforts to improve 
vaccination coverage, particularly in LBW and VLBW infants, should continue.
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Before the introduction of 2 rotavirus vaccines, RotaTeq (RV5) in 2006 and Rotarix (RV1) in 
2008, rotavirus was the leading cause of acute gastroenteritis (AGE) for US children <5 
years of age.1 Rates of severe all-cause AGE and rotavirus AGE among the US pediatric 
population have declined dramatically since postvaccine introduction,2 with well-
documented direct and indirect effects of vaccination.3–5
In 2015, approximately 8% of all US births were of low birth weight (LBW, <2500 g) and of 
those, 1.4% were of very low birth weight (VLBW, <1500 g).6 As compared with normal 
birth weight (NBW) infants, LBW and VLBW infants are at increased risk for severe 
rotavirus AGE7,8 and associated complications.9,10
Because of small sample sizes, the efficacy of rotavirus vaccines in low birth infants could 
not be well evaluated in prelicensure clinical trials.11,12 However, given that the vaccine was 
well tolerated and immunogenic in these infants and given that LBW infants are at increased 
risk of severe AGE, the US Advisory Committee on Immunization Practices recommends 
that LBW infants, including those who are premature, receive rotavirus vaccination at the 
same schedule as NBW infants provided they are age eligible for vaccination (6–14 weeks 
of age for dose 1), are clinically stable, and vaccine is administered at the time of or after 
discharge from the neonatal intensive care unit (NICU) or nursery. However, because some 
low birth infants may be >14 weeks of age at the time of discharge from the NICU or 
nursery, they may no longer be age eligible to receive rotavirus vaccination.1
Using a large national administrative claims database, we assessed the impact of rotavirus 
vaccination in reducing AGE hospitalizations comparing high risk vaccinated to high-risk 
unvaccinated children in the postvaccine era. Additionally, we examined if rotavirus vaccine 
coverage rates among LBW and VLBW infants differed from their NBW counterparts.
MATERIALS AND METHODS
We retrospectively analyzed longitudinal cohort data from Truven Health MarketScan 
Commercial Database (Truven Health Analytics, Ann Arbor, MI), which constitutes 
insurance claims from deidentified enrollees <65 years of age participating in employer-
sponsored insurance plans. The MarketScan data are generalizable to the US population that 
are on employer-sponsored plans which encompasses approximately 58% of the US 
population. Medicaid recipients are not included. In 2015, enrollment data from almost 30 
million primary beneficiaries and their dependents were captured. Our study population 
included data from approximately 3 million children <5 years of age from years 2001–2015 
with data available from the monthly enrollment and inpatient Marketscan databases.
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LBW infants were defined as newborns with International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes: 765.01–765.18 (excluding 765.09, 
765.10) indicating a birthweight <2500 g, whereas NBW infants were defined by the 
absence of a LBW ICD-9-CM code; VLBW infants (ie, birthweight <1500 g) were those 
with codes: 765.01–765.05, 765.11–765.15. AGE hospitalizations were identified based on 
the presences of the following ICD-9-CM codes: viral enteritis, 008.6–008.8 (including 
rotavirus, 008.61); bacterial enteritis, 001.0–005.9 (excluding 003.2) and 008.0–008.5; 
parasitic intestinal disease, 006.0–007.9 (excluding 006.3–006.6); presumed infectious 
diarrhea, 009.0–009.3; presumed noninfectious diarrhea, 558.9 and diarrhea not otherwise 
specified, 787.91, occurring in at least 1 of 15 possible discharge diagnoses fields from the 
inpatient admissions database.
Rotavirus Vaccine Coverage
RV5 and RV1 coverage was assessed for 2006 to 2015 and was defined as the receipt of at 
least 1 dose of either vaccine type among children who were continuously enrolled from 
birth until at least 3 months of age. Current Procedural Terminology was used to define 
receipt of RV5 or RV1 based on Current Procedural Terminology codes (RV5 = 90680, RV1 
= 90681). The continuous enrollment criteria ensured that infants had the opportunity to 
receive at least 1 dose of a rotavirus vaccine.
When assessing vaccine trends, states with universal vaccine programs at any time during 
the study period were removed to control for bias in vaccine coverage rates as data on 
receipt of vaccination may not have been captured in MarketScan in these states.13 From 
2007–2012, 13 states provided RV vaccines through a state-sponsored childhood vaccine 
program (Alaska, Idaho, Maine, Massachusetts, New Hampshire, New Mexico, North 
Dakota, Oregon, Rhode Island, Vermont, Washington and Wisconsin, Wyoming). In 2013–
2014, the number decreased to 11 states (same states in 2007–2012 with exception of 
Alaska, North Dakota, Oregon and Wisconsin and the inclusion of Connecticut and South 
Dakota). In 2015, 10 states provided RV vaccines as part of their universal vaccination 
program (Alaska, Idaho, Maine, Massachusetts, New Hampshire, New Mexico, Rhode 
Island, Vermont, Washington and Wyoming). According to the National Immunization 
Survey, the 2015 median (range) of rotavirus vaccine coverage rates among children 19–35 
months of age for the 15 states excluded was 75% (71%–88%) as compared with 73% 
(64%–83%) in states without a state-funded vaccine program.14 To better ensure the validity 
of our vaccine coverage estimates, we also compared coverage trends for receipt of at least 1 
dose for the diphtheria, tetanus and acellular pertussis (DTaP) vaccine. Administration of the 
first dose of DTaP is recommended at the same time as the rotavirus vaccines which could 
then be compared with well-established coverage rates captured by National Immunization 
Survey.
AGE and Rotavirus Hospitalization Trends
Annual rates for both all-cause AGE and rotavirus AGE hospitalization were calculated for 
children <5 years of age. July 2007 to June 2015 were considered postvaccine introduction 
years and July 2001 to June 2006 as prevaccine years. July 2006 to June 2007 was excluded 
from pre/postvaccine introduction analyses and was considered a transitional year because 
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rota-virus vaccine uptake was low and uneven across the country. Enrollment data and 
annual rates were calculated using number of child enrollment days contributed per year 
divided by 365.25. Rates were adjusted for seasonality with rates calculated based on birth 
month-year for both annual July–June and peak January–June seasons. Poisson regression 
was used to assess trends in AGE and rotavirus hospitalization rates during the study period. 
All states, including the universal states, were included in the trends analysis.
Rotavirus Vaccine Effectiveness
For the postvaccine years from July 2008 to June 2015, we assessed the annual effectiveness 
of the rotavirus vaccines in eligible populations by comparing AGE hospitalization rate 
reductions among vaccinated infants to unvaccinated infants for LBW, VLBW and NBW 
infants. The population were children who were age eligible to receive at least 1 dose of 
RV5 or RV1 before the start of each July–June season, that is, 3–23 months of age by each 
July and were continuously enrolled through the rotavirus season, that is, through June of 
each season. Our postvaccine study period starts in July 2008 as RV5 vaccine coverage by 
birth month was unstable before this time. Analysis was restricted to include no more than 1 
diarrheal event per enrollee per season. Rates were assessed for children <2 years of age. 
Children from the states with universal vaccine programs were also excluded.
Baseline rates for prevaccine years were calculated for children <2 years of age. We used 
Poisson regression to adjust for hospitalization rates by birth quarter and reported the rate 
reductions and 95% confidence intervals (CIs) for receipt of at least 1 dose of either 
rotavirus vaccine.
RESULTS
Rotavirus Vaccination Coverage
Our final cohort included approximately 2 million children <5 years of age of which 96% 
were identified as NBW and 4% were defined as LBW. Among the LBW infants, 24% also 
met the VLBW criteria. RV vaccination coverage trends for all weight groups (that is, NBW, 
LBW and VLBW) were similar with increasing coverage rates since introduction of RV5 in 
2006 and RV1 in 2008. As of December 2014, coverage among infants who had received at 
least 1 dose of RV5 or RV1 was near 90% for the NBW cohort and 82% and around 64% for 
the LBW and VLBW groups, respectively. The difference in RV coverage among the LBW 
and NBW was statistically significant (p < 0.0001). Comparatively, DTaP coverage was over 
90% for both the NBW and LBW and 85% in the VLBW group (Fig. 1).
Of the 12,421 eligible VLBW infants who received at least 1 dose of a rotavirus vaccine, 
77% received their first dose at or before 14 weeks of age compared with over 90% for both 
the NBW and LBW infants (Table 1). Results were comparable when reviewing DTaP 
coverage among the same cohort. Among all children <5 years of age, as of December 2014, 
RV vaccine coverage rates were similar for both NBW and LBW at 84% and 80%, 
respectively, while the VLBW coverage rate was 65% (Table, Supplemental Digital Content 
1, http://links.lww.com/INF/C977). Overall RV vaccine coverage has steadily increased 
since the vaccines were introduced for all age and weight groups.
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AGE and Rotavirus Hospitalization Trends
Similar to the coverage estimates, this analysis included approximately 2,256,000 children 
<5 years of age with comparable proportions in each weight group. Rates of all-cause AGE 
and rotavirus AGE hospitalization were greatest among VLBW infants, followed by LBW 
infants, and lowest in NBW infants in both pre- and postvaccine years. The rates of AGE 
hospitalizations in all groups have continued to decline since the introduction of the RV 
vaccines though variations in the impact of the vaccines can be seen from year to year (Fig. 
2). Additionally, a biennial pattern of rotavirus seasonality emerges for the cohorts which is 
also evident among the AGE hospitalizations though the pattern is less distinct among the 
LBW and VLBW cohorts.
In the prevaccine years, 2001–2006, the rate of both rotavirus-coded and AGE 
hospitalizations among the LBW and VLBW cohorts was higher than the rates in the 
postvaccine years, 2014–2015. The effect was evident across all age groups though the 
magnitude and significance of the impact varied (Table 2). For <5-year olds, the mean 
prevaccine rotavirus-coded hospitalization rate for LBW infants was 38 per 10,000 person-
years as compared with 1 per 10,000 person-years in 2014–2015 for an overall reduction of 
98% (95% Cl: 93%–100%). Comparatively, the VLBW prevaccine rate was 43 per 10,000 
person-years and in 2014–2015, the rate was 3 per 10,000 person-years for an overall 
reduction of 93% (95% CI: 70%–98%).
For the same time frame, similar rotavirus-coded hospitalization reductions were noted in all 
age groups (ie, <1, 1, 2–4 and <5 years) showing declines ranging from 90% to 100% in the 
VLBW groups and 97% to 100% in the LBW children. AGE hospitalization rates also 
declined among all birth weight groups. Among <5- year olds, the mean prevaccine rate in 
the LBW group was 156 per 10,000 person-years as compared with 195 per 10,000 person-
years in the VLBW infants. The 2014–2015 LBW rate reduction was 64% (95% CI: 57%
−70%) and 55% (95% CI: 39%−67%) in the VLBW cohort.
Across all postvaccine annual seasons, age groups and weight classes, the LBW age groups 
for 1-year olds and 2- to 4-year olds reported the largest declines in 2014–2015 with an 
overall reduction in AGE hospitalizations of 70% (95% CI: 57%–79% and 95% CI: 53%–
80%, respectively), when compared with the prevaccine rate. Similar trends were evident 
during the peak rota-virus months of January to June with annual rate reductions for both 
rotavirus-coded and AGE hospitalizations in all weight groups for children <5 years old 
(Table, Supplemental Digital Content 2, http://links.lww.com/INF/C978).
Rotavirus Vaccine Effectiveness
For season 2014–2015, among the 1,300,000 age-eligible children <2 years of age, AGE 
hospitalization rates for those who received at least 1 dose of a rotavirus vaccine were lower 
compared with their unvaccinated counterparts (Table 3). In 2008–2009, the first full season, 
there was a rate reduction for all weight classes with a decline of 49% (95% CI: 42%–55%), 
60% (95% CI: 36%–75%) and 75% (95% CI: 17%–93%) in the NBW, LBW and VLBW 
groups, respectively. During 2014–2015 season, among LBW children who had received at 
least 1 dose of RV5 or RV1, there was 72% (95% CI: 44%–86%) reduction and a 71% (95% 
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CI: 7%–91%) decline among the VLBW infants as compared with infants who did not 
receive a dose of either RV vaccine. Among the NBW infants, similar trends were noted 
with a 62% (95% CI: 51%–71%) reduction which is the greatest reported decline among this 
group since introduction of the rotavirus vaccine. Because of small numbers, we did not 
report on rate reductions for rotavirus- coded hospitalizations.
DISCUSSION
RV vaccination coverage increased for all age groups over the study period. As of 2014–
2015, <1-year olds were covered at 89%, 84% and 68% for the NBW, LBW and VLBW 
infants, respectively, the highest coverage achieved since the introduction of the rotavirus 
vaccines. However, disparities were evident when comparing coverage among the different 
weight classes with the VLBW group consistently lagging behind the NBW children. While 
DTaP vaccination coverage showed similar trends, the disparities among the weight groups 
were less pronounced. One possible reason for the lower RV compared with DTaP coverage, 
especially among the VLBW infants, is that many of these infants may not be age eligible to 
receive the first dose of rotavirus vaccine if they were older than 14 weeks when discharged 
from the NICU. This hypothesis is supported by our data that among eligible infants who 
received at least 1 dose of the RV vaccine, only 5% of the NBW infants received their first 
RV dose after 14 weeks of age as compared with 23% in the VLBW groups. Additionally, it 
is important to note that almost a quarter of the vaccinated VLBW cohort received their first 
RV dose outside the US Advisory Committee on Immunization Practices recommended 
vaccination schedule. Our data suggest that when addressing the risk of exposure and burden 
of rotavirus disease, clinicians might be opting to administer the first RV dose off 
recommendation versus risking a missed opportunity for vaccination.
Overall hospitalizations among US children <5 years of age caused by AGE and rotavirus 
have declined substantially since the introduction of the 2 US-licensed rotavirus vaccines. 
Throughout the study period, we found that AGE hospitalization rates were higher among 
VLBW infants as compared with LBW and NBW cohorts. However, the hospitalization rate 
reductions were slightly greater among LBW infants relative to the VLBW cohort, possibly 
because of lower rotavirus vaccine coverage among VLBW compared with LBW infants. 
Nevertheless, large declines in AGE hospitalization rates of 64% and 55% were reported in 
2014–2015 among LBW and VLBW infants, respectively, demonstrating that rotavirus 
vaccines have had a substantial health impact in these high-risk infants, similar to the 
general population of US infants. Our results also demonstrate the high effectiveness of 
rotavirus vaccines in reducing AGE hospitalizations in vaccinated infants as compared with 
their unvaccinated counterparts among LBW and VLBW infants, at levels similar to those in 
NBW infants. Taken together, these data support the use of rotavirus vaccines in all US 
infants, including LBW and VLBW infants.
Limitations of this study include the lack of descriptive information for enrolled children, 
including race and socioeconomic status. We also only assessed infants who were privately 
insured thereby excluding LBW and VLBW infants who are on Medicaid, under-insured or 
uninsured. Given that approximately 8% of all US infants are born at a LBW6 and that 
among them over 50% are on Medicaid15; our results may not be generalizable to the entire 
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US population of LBW infants. Finally, because of small numbers, we were unable to 
describe the hospitalization rates among infants born at extremely LBWs (<1000 g).
CONCLUSIONS
Our study illustrates the substantial impact the rotavirus vaccines have had on dramatically 
reducing the rates of AGE and rotavirus hospitalizations among US children <5 years of age, 
and provide the first evidence of the large impacts in LBW and VLBW children. Efforts to 
improve vaccination coverage, particularly in LBW and VLBW infants, should continue.
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FIGURE 1. 
Three-month moving average of rotavirus and DTaP vaccine coverage among eligible NBW, 
LBW and VLBW infants enrolled in MarketScan, 2007–2015 (eligible infants were those 
who were continuously enrolled from birth until at least 3 months of age while coverage was 
defined as receipt of at least 1 dose of vaccine. Children from universal vaccine states were 
excluded).
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FIGURE 2. 
Acute gastroenteritis and rotavirus-coded hospitalization rates among children <5 years of 
age, 2003–2015.
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TABLE 1.
Timing of First Rotavirus Dose According to Weight Group, 2007–2015*
Vaccinated
Infants
No.
Recommended
Schedule†
No. (%)
Delayed
Schedule‡
No. (%)
Normal birth weight 1,541,183 1,469,847 (95) 71,336 (5)
Low birth weight    65,867    60,073 (91)    5794 (9)
Very low birth weight    12,421     9536 (77)    2885 (23)
*Vaccinated infants were those who were continuously enrolled from birth until at least 3 months of age and had receipt of at least 1 dose of a 
rotavirus vaccine. Children who were from a universal vaccine state were excluded.
†
Recommended schedule was defined as receipt of the first dose of a rotavirus vaccine ≤104 days.
‡
Delayed schedule was defined as receipt of the first dose of a rotavirus vaccine >104 days.
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